Abstract The arrival of personalized medicine in the clinic means that treatment decisions will increasingly rely on test results. The challenge of limited healthcare resources means that the dissemination of these technologies will be dependent on their value in relation to their cost, i.e., their cost effectiveness. Phelps and Mushlin have described how to optimize tests to meet a cost-effectiveness target. However, when tests are applied repeatedly the case mix of the patients tested changes with each administration, and this impacts upon the value of each subsequent test administration. In this article, we present a modification of Phelps and Mushlin's framework for diagnostic tests; to identify the cost-effective cut-off for monitoring tests. Using the Ca125 test monitoring for relapse in ovarian cancer, we show how the repeated use of the initial cut-off can lead to a substantially increased falsenegative rate compared with the monitoring cut-off-over 4 % higher than in this example-with the associated harms for individual and population health.
We show that the extent of this difference, and hence its importance to clinicians, patients, and decision makers depends upon the underlying prevalence of the condition, test performance characteristics of the test at its first administration, rate of disease progression, and the interval between test administrations, as well as the target costeffectiveness threshold.
Decision makers are likely to be interested in the impact of changing the cost-effectiveness threshold on the optimal case definition cut-off value; hence, we present the cost-effectiveness threshold curve, which is able to identify the optimal case definition cut-off value corresponding to each costeffectiveness threshold.
The framework developed by Phelps and Mushlin, and extensions, such as the ones we have described here, offer a formal decision analytic approach identifying the cut-off that optimizes the contribution of these technologies to population health in a given healthcare system.
Introduction
The advent of personalized medicine and whole genome screening seek to place testing at the heart of everyday clinical care. An inevitable result of this potential revolution in healthcare is that reimbursement authorities will have to assess the cost effectiveness of tests and testdirected therapies with increasing frequency. Historically, tests have represented a small component of health technology assessment activity and they have not been the focus of methods development to the same degree as many other technologies. However, reimbursement authorities are increasingly interested in how to appraise these technologies and in some cases have established bespoke processes for just this purpose [1, 2] . Establishing how to incorporate these new technologies into the health technology appraisal and value-based pricing frameworks is an increasingly important challenge.
The seminal work on the assessment of the cost effectiveness of tests was published by Phelps and Mushlin (PM) in 1988 [3] . In this work, they described how to identify the diagnostic test cut-off that would meet a cost-effectiveness target. However, the personalized medicine revolution described by its advocates [4] conceives of the repeated application of these tests to monitor an individual's health, and in people with a diagnosis, the progression of disease. There are already some personalized medicine tests available that are designed for monitoring, including prostatespecific antigen for prostate cancer, Ca125 test for ovarian cancer, and the enhanced liver fibrosis test [5] [6] [7] . When a test is used for monitoring, the results of the first administration of the test and responses to it change the case mix of patients at the second administration of the test, and this may impact upon the test performance characteristics and hence the value of the test using the initial test cut-off value.
The objective of this paper is to present an extension of the framework developed by PM [3] for assessing diagnostic tests, for monitoring tests. Specifically, we aim to describe the factors that may drive a difference in the cost-effective cut-off between the first and subsequent applications of the same test; present a formal framework for identifying the cost-effective cut-off for sequential monitoring tests, and present a worked example of the extended framework using Ca125 monitoring test data in the context of ovarian cancer.
The remainder of the paper is structured as follows: Section 2 briefly reviews PM's [3] model for assessing diagnostic technologies. Section 3 describes the model that we used to impose the conditions of differentiability and convexity to the empirically derived receiver operator curve (RoC). Section 4 describes how the monitoring test context is systematically different from the diagnostic test one and presents an extension of the PM model to sequential monitoring tests; which is then applied to the use of the tumor marker Ca125 to monitor disease activity in ovarian cancer [6] in Sect. 5. Section 6 discusses the implications of the results of the case study analysis and presents a new output for test cost-effectiveness analysesthe cost-effectiveness threshold curve. Section 7 summarizes the arguments for and implications of adopting costeffectiveness criteria in developing new test technologies, such as will be required for the realization of the personalized medicine revolution.
Identification of the Cost-effective Case Definition
Cut-Off for the Diagnostic Test PM [3] developed a theoretical framework for determining the expected value of diagnostic information with a twostep approach. In the first step (''hurdle 1''), perfect sensitivity and specificity of the diagnostic technology are assumed. It is required that the expected value of perfect information is higher than the cost of using the new technology for it to access the second step (''hurdle 2'') of evaluation, whereby the test has less than perfect sensitivity and specificity. Likewise, hurdle 2 would be overcome if the expected value of the imperfect information exceeds the cost of using the diagnostic technology. The decision theoretic model of PM can also be used to identify the case definition cut-off to meet a pre-specified cost-effectiveness threshold. In this section, we briefly review PM's framework.
Consider a diagnostic test that dichotomises the subsequent management strategy dependent upon those results. The actual patient benefits and costs will depend upon true health states and how well the test can identify these (e.g., in terms of characteristics of the RoC, such as area under the curve [8] ). Ideally, the information from the diagnostic test will be interpreted to best benefit the patient and to be cost efficient, by identifying the case definition cut-off corresponding to the cost-effective combination of sensitivity and specificity at the relevant threshold for cost effectiveness. In PM, this can be done in a general optimization setting, using the same probability, utility, and cost data required for calculating the value of diagnostic information and for which the authors define the following notation: Then, we define the cost-effectiveness threshold that we wish to optimize the test for. Consider the health gains achievable if the resources needed for the proposed test were put to use in the least favorable procedure that was still acceptable, i.e., the first activity that would be dropped to provide others in a resource-constrained environment [9] . We denote the effectiveness-to-cost ratio (in qualityadjusted life-years [QALYS]/£) of this marginal activity as g.
The sensitivity of the test can be increased at the cost of reduced specificity, or vice versa, by varying the cut-off, which we denote as k d , used to establish the diagnosis.
In general, we wish to maximize the net benefit of the test (NB d ) for the patient with respect to p d and q d ; where p d is sensitivity and q d is 1À specificity.
From Eqn. (A11) in PM [3] , it can be shown that:
We can find combinations of p d and q d in which the net benefit remains the same, by taking the differential of Eq. (1), allowing p d and q d to vary jointly, but holding the total change in
The optimal choice, i.e., that which maximizes the expected net benefit of the test with respect top d andq d , is then found (see [3] ) by setting:
In Eq. (2), we are selecting the cut-off k d that identifies a point on the RoC with slope b d as shown in Fig. 1 below.
Thus, given a specified cost-effectiveness threshold, such as that used by the UK National Institute for Health and Care Excellence (NICE) [10] , knowledge of the costs and outcomes of treatments for true and false negatives and positives, as well as the RoC for a diagnostic test, it is possible to identify the case definition cut-off that will lead to the test being a cost-effective addition to the portfolio of services provided.
Fitting a Receiver Operator Curve Model
To identify a unique point on a RoC from its slope, it is necessary for the curve to be both smooth (differentiable) and convex. Moreover, it can be shown that non-convexity in a RoC implies the use of an irrational decision strategy [11] . Empirically derived RoCs do not necessarily satisfy these conditions and hence we impose them by fitting a model to the empirical curve. The model is then used to derive the slope for the optimal sensitivity, specificity, and cut-off as identified by PM methods (suitably modified when applied in a monitoring context).
The most common RoC model is the binormal [12] . This model assumes biomarker values are normally distributed in both the population of patients that are in remission and the population of patients whose cancer has recurred, but allows the means and standard deviations in the two populations to differ. The binormal model has the advantage that its slope for a particular sensitivity and specificity pairing can be derived analytically [13] . However, in many applications the normality assumptions are not satisfied [14] and the model curve, although differentiable, is not convex (and hence a slope value does not indentify a unique point on the curve).
As a refinement to the binormal model, Metz et al. [15] proposed a more flexible, latent variable approach whereby it is assumed that some monotonic transformation of the biomarker values yield normal distributions. Maximum likelihood fitting of this latent variable binormal model is implemented in the ROCKIT software provided by the Metz lab (http://metz-roc.uchicago.edu/). Although the latent variable model does not impose convexity on the fitted curve, in many applications where large samples of data are available for continuous biomarkers, the convexity property holds [16] . The ROCKIT software can be used to identify both the sensitivity and specificity pairings that form the model curve and the underlying biomarker cut-off values for a particular pairing used in predicting remission/ recurrence status. Although no analytical method is available to determine the slope of latent variable RoC, numerical derivatives are easily obtained (e.g., by finite difference see, for example, Burden and Faires [17] ).
As a further extension of the binormal model, Pesce and Metz [18] describe a ''proper'' binormal model, whereby convexity is imposed on the curve. This is of particular importance when models are fitted to small samples or where biomarkers are ordinal rather than continuous. Current software to fit the ''proper'' binormal model provided by the Metz lab can be used to identify sensitivity and specificity pairings that form the model curve for use, e.g., in identifying performance measures such as the area under the RoC. However, the software does not yield the underlying biomarker cut-off values for a particular pairing to predict remission/recurrence status. Therefore it cannot be used to identify optimal cut-offs for the PM method.
Given that for the Ca125 data example (described in Sect. 5) we have a continuous biomarker and a large sample size, we adopt the latent variable model of Metz et al. [15] . Convexity and model fit has not proved problematic in this application, although we acknowledge that in other data sets further work on software to identify cutoff values for the ''proper'' binormal model may be required.
Sequential Monitoring Tests
Developing on the framework described in Sect. 2, consider the use of the same test for monitoring. There are a number of circumstances in which a test may be used for monitoring purposes. The first is when the result from the first administration of the test is negative. In patients who have a clear predisposition for the condition of interest, periodic re-application of the same test is an obvious management strategy. Clinicians may also choose to readminister the test in patients who test positive on the first administration. If the natural history of the disease allows for remission or if treatment is expected to achieve remission then monitoring is also a sensible strategy. Tests may also be re-administered when there are concerns about the test-re-test reliability. However, this is not a monitoring activity as it is concerned with the performance characteristics of the test rather than capturing changes in the patient's clinical condition. An illustration of the process is shown in Fig. 2 above.
If -ve . Note that the subsequent tests are not different from the initial test; they are just administered to different subgroups in a subsequent point in time. The key observation is that the patients presenting for monitoring tests D 2?ve and D 2-ve have a different probability of being sick (prevalence) compared with the general population of patients presenting for the initial test; whilst the costs, utilities, and health gains of treatment remain the same.
The probability that a patient presenting for tests D 2?ve and D 2-ve is sick depends on the positive predictive value and negative predictive value of test D 1 , with an adjustment term to allow for disease progression. To address this analytically we need to define some additional terms. Define:
where f 2þve and f 2Àve represent the prevalence of disease of patients presenting for subsequent tests; q is a direct function of time and is the probability a patient is sick when presenting for test D 2?ve or D 2-ve , given they were not sick when presenting for test D 1 (i.e., the probability that a healthy person presenting for test D 1 becomes sick because of disease progression before presenting for test D 2?ve or D 2-ve ); r 1 and s 1 are respectively the positive predicted value and the negative predicted value of test D 1 . Thus, Eq. (3) represents the probability that a person presenting for test D 2?ve will be sick and Eq. (4) represents the probability a person presenting for test D 2-ve will be sick. By an analogous argument to that presented in Sect. 2, it follows that optimal cut-offs k 2?ve and k 2-ve can be 
If the arguments presented above are accepted, it is clear that cut-off values k. for further monitoring tests proceeding D 2?ve and D 2-ve can be identified. To do so, the proportion of sick patients presenting for further investigation need only be updated to reflect the positive predictive value and the negative predictive value of tests D 2?ve and D 2-ve , with appropriate modification for further disease progression up to the point in time when the subsequent tests would be performed. In fact, being q a direct function of time, if the test is performed at an earlier or later point in time, the estimate of true negatives that are expected to become true positives in the interval between test administrations would change as well.
Furthermore, PM identify the circumstances under which a test creates net value (see Eqs. (4-6) in [3] ). If the clinician's default choice prior to testing is to treat, then the test should be employed if:
Similarly, if the clinician's default choice prior to testing is not to treat, then the test should be employed if:
We suggest that Eqs. (7-8) can be used to identify the point in a testing sequence when further tests are not cost effective. We also argue that (7-8) offer a framework that can account for quality of life and costs accrued over an extended time horizon.
Identifying the Optimum Monitoring Test Cut-offs for the Ca12Test in the Management of Ovarian Cancer
For the purposes of this example, we constructed a stylized cost-effectiveness model of monitoring ovarian cancer patients with Ca125, to identify relapse and trigger chemotherapy. The model uses a 12-month time horizon as there was no difference in mortality between Ca125-and symptom-guided therapy observed in the MRC OV05 trial [6] . The outcome used in the model was the QALY with utility weights for sick patients, both treated and untreated taken from the NICE Clinical Guideline for Ovarian Cancer [19] ; and utility weights for healthy patients taken from Kind et al. [20] . The costs of care are also taken from the NICE Clinical Guideline [19] . Model parameters are summarized in Table 1 .
Ca125 Test Data
The anonymized clinical data used for this analysis were extracted from the central clinical database used by oncology services in the Leeds Teaching Hospitals National Health Service (NHS) Trust. Six hundred consecutive patients with a diagnosis of ovarian cancer after 1st January 2004 were included in the analysis. Patients of all stages at diagnosis were included, irrespective of initial or subsequent treatments. The most common management course consists of initial primary treatment with surgery or chemotherapy or both treatments. The majority of patients' cancers will respond either completely or partially to this initial treatment, following which they enter a period of monitoring; monitoring consists of clinical assessment, Ca125 measurement (kiloUnits per liter in our clinical data), and computer tomography (CT) scanning. After entering a monitoring period, further treatment with chemotherapy is usually initiated on the basis of a clinical decision that there is sufficient evidence of cancer progression based on CT and clinical assessment. A rising Ca125 will typically prompt a CT scan, but will only rarely, in isolation, result in treatment without confirmatory CT or clinical evidence of progression. Progression status is accurately coded in this clinical dataset. We refer to our clinical outcome as 'disease progression' or 'disease control'. The term disease progression is used for consistency where cancer has grown, recurred, or relapsed. Disease 
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control is used as a summary term representing tumor shrinkage, stability, remission, or possible cure. A truepositive Ca125 test is defined as a Ca125 measurement followed in less than 30 days by a CT scan showing progression. A true-negative Ca125 measurement is defined as a marker measurement that is not followed within 30 days or preceded within 30 days by a diagnosis of progression (from CT scan or commencement of treatment).
Cost-effective Case Definition Cut-Off
To calculate the cost-effective cut-off for the test at its first administration we used Eq. 2 above (from PM) and solved using the values in Table 2 . The prevalence of progressive ovarian cancer in this dataset was 33 % at the time of the first administration of the test, using the definition described above. The utility gain from not treating a healthy person is DU h = 0.1, i.e., a person not in need of treatment benefits from not receiving chemotherapy, which would cause them extensive side effects. Conversely, the utility gain from treating a sick person is DU s = 0.18, i.e., the treatment is effective.
With regard to costs, given that everyone in the sample is administered the diagnostic test and, given the simplified framework described above, the change in cost from treating a sick person shows just the chemotherapy cost, DC s = £316.29; whilst the change in cost from not treating a healthy person is the chemotherapy cost avoided, DC h = -£316.29.
Finally, g = 0.00005 is the inverse of NICE's willingness to pay threshold, i.e., the minimum QALY gain the NHS is willing to accept when spending £20,000 on an intervention.
The optimum slope identified with these parameter values is 1.44, which corresponds to a case definition cutoff of 127.94 kU/L (Table 2); i.e., this is the cut-off that delivers improvement in patient outcomes with an incremental cost-effectiveness ratio that is equal to the costeffectiveness threshold. With this case definition cut-off, sensitivity = 67 % and specificity = 79 %. This means that, with an underlying prevalence of 33 % at time 1, 22 % of ill patients will be correctly identified as progressed; whilst the remaining 11 % will be incorrectly identified as under control. As the underlying prevalence of the condition increases, the optimal test cut-off decreases. Likewise, as the cost of missed diagnoses increases the optimal test cut-off decreases.
For ease of exposition of the issues around test optimization for monitoring, we narrow the discussion of sequential testing to a subset, i.e., the re-administration of a test following an initial negative test result, the 'control disease' group in our example. To identify the cost-effectiveness cut-off for the subsequent application of the test, we need to specify the prevalence of the disease in the group that the initial test defined as having controlled disease (testing negative on D 1 ). At a cut-off of 127.94 kU/L, the negative predictive value of the test is 0.611, and the positive predictive value is 0.831. When this is combined with a disease progression rate of 20 %-i.e., with 20 % of those initially under control experiencing recurrence between surveillance timepoints-the prevalence of disease in the controlled group is 50 %. The new cut-off identified is significantly lower than at the first administration, 42.53 kU/L, with sensitivity = 86 % and specificity = 61 %. With this case definition cut-off, 43 % of ill patients will be correctly identified as progressed; whilst the remaining 7 % will be incorrectly identified as under control.
In the controlled disease group, only a very low test result is required to confirm the presence of progressive disease in a cost-effective manner.
Using Cost-effective Test Cut-Offs
The choice of g, the cost-effectiveness threshold used in the optimization analysis is a key decision. Conceptually, it is likely that the cost-effectiveness threshold will differ between health systems because the threshold is a function of the health system's budget, the portfolio of the current therapies it provides, and the demand for those therapies from the population it serves [9] . Given the complexity of the determinants of the cost-effectiveness threshold, it is perhaps unsurprising that there is substantial disagreement about the appropriate choice of threshold value even within a health system [21] [22] [23] . As a result, decision makers are likely to be interested in the impact of changing the costeffectiveness threshold on the optimal case definition cutoff value. Figure 3 illustrates the cost-effectiveness threshold curve for the Ca125 test in ovarian cancer. The optimum case definition cut-off is plotted on the vertical axis and the cost-effectiveness threshold, sometimes called the willingness to pay for health, is plotted on the horizontal axis. We can see that in this case, as the willingness to pay for health increases from £5,000 to £10,000 both the initial and sequential cut-off for patients assessed with controlled disease drop substantially, but any further increases have only a moderate impact. For the exemplar test, most health systems are likely to use a willingness-to-pay value that is in the less sensitive range. However, it is credible that for other tests different health systems might operate very different test cut-off scores, reflecting the large differences in their willingness to pay. This ability to identify a cut-off value at which a test is cost effective may be attractive to budget holders who wish to avoid simple accept or reject decisions for personalized medicine technologies, by allowing them to use companion diagnostics to identify the sub-group of patients in whom treatment is cost effective.
Discussion
In this article, we have shown how the model of PM for identifying the cost-effective case definition cut-off for a diagnostic test can be extended to monitoring tests; and how the test cut-off that is cost effective in the investigation at time 2 may be quite different from the one that is cost effective at time 1. The notion of prevalence varying under repeat testing necessitating a difference in cut-offs is discussed (though not developed) in the recent article [24] . We show that the extent of this difference, and hence its importance to clinicians, patients, and decision makers depends upon the underlying prevalence of the condition, test performance characteristics of the test at its first administration, rate of disease progression, and the interval between test administrations, as well as the target costeffectiveness threshold. In our example, that difference in cut-off levels means that in the application at time 2, the test returns a higher true-positive rate and a lower falsepositive rate than the test at time 1. In fact, we have a higher proportion of ill patients correctly identified as such; 43 % identified using the subsequent cut-off, compared with 22 % using the initial cut-off. We also observe a lower proportion of ill patients incorrectly identified as under control; 7 % using the subsequent cut-off compared with 11 % using the initial cut-off. Specifically, the repeated use of the initial cut-off leads to an increased falsenegative rate-4 % higher in this example-with the associated harms for individual and population health.
The results presented in this paper consider monitoring in patients whose initial test result is negative. Monitoring after a positive test result can occur when remission is part of the natural history of the disease or when treatment is aimed at achieving remission. In principle, the framework described in Sect. 4 could be used in these circumstances by incorporating a probability of disease remission. The impact of remission on costs and outcomes of care is unlikely to be a simple reversal of the costs and outcome impact of progression. Including these forms of monitoring in the exemplar analysis would have increased the complexity without adding substantially to its value.
A limitation of this article is the time horizon of the example, for which we constructed a stylized model to illustrate the potential importance of the issue. The magnitude of divergence between using the optimal monitoring strategy and the initial diagnostic strategy will be determined by a number of factors, such as the natural history of disease and the divergence in costs and outcomes for each testdependent clinical strategy. However, the more valuable the test, the higher the impact of a correct clinical strategy will be. Therefore, it is likely that the issue is more important with highly informative tests and highly effective treatments.
As healthcare systems increasingly turn to cost-effectiveness-based decision criteria, including value-based pricing, to determine which innovative technologies are reimbursed, developers of these test-dependent technologies will need to consider the relationship between their choice of cut-off and the number of markets that are likely to view their technology as a good use of limited healthcare resources, and thus the likely sales revenue. Alternatively, developers may wish to simply provide healthcare systems with the RoC characteristics for their technologies and allow each system to identify its own case definition cut-off, or cut-offs in the case of monitoring tests, at which the test is good value.
Conclusions
The potential tsunami of diagnostic tests that the proposed personalized medicine revolution is bringing forth, will drive healthcare budget holders away from accepting conventional individual patient level clinical utility as a sufficient justification for the choice of case definition. Net health benefit at the population level will be an important part of the justification of any particular cut-off. The framework developed by PM, and extensions, such as the ones we have described here, offer a formal decision analytic approach identifying the cut-off that optimizes the contribution of these technologies to population health in a given healthcare system.
